Compare DLY & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DLY | VSTM |
|---|---|---|
| Founded | 2019 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 705.8M | 723.8M |
| IPO Year | N/A | 2012 |
| Metric | DLY | VSTM |
|---|---|---|
| Price | $14.70 | $6.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $13.38 |
| AVG Volume (30 Days) | 215.9K | ★ 2.1M |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 8.93% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,379,000.00 |
| Revenue This Year | N/A | $208.54 |
| Revenue Next Year | N/A | $251.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 33.79 |
| 52 Week Low | $13.26 | $4.01 |
| 52 Week High | $15.95 | $11.25 |
| Indicator | DLY | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 52.39 | 36.02 |
| Support Level | $14.67 | $6.68 |
| Resistance Level | $14.92 | $7.26 |
| Average True Range (ATR) | 0.09 | 0.59 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 53.33 | 10.29 |
DoubleLine Yield Opportunities Fund is a diversified, limited-term, closed-end management investment company. Its investment objective is to seek a high level of total return, with an emphasis on current income. The company invests in debt securities and other income-producing investments of issuers anywhere in the world, including in emerging markets, and may invest in investments of any credit quality. Its investment portfolio comprises foreign corporate bonds, foreign government bonds, non-agency commercial mortgage-backed obligations, U.S. corporate bonds, collateralized loan obligations, and bank loans among other securities.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.